Search research articles
Contact Us
Filters
Showing results (21-30 of 51) with videos related to
Page
of 6
Sort By:
AIDS (London, England)
|
May 24, 2022
Anti-CD4 autoantibodies in immunological nonresponder people with HIV: cause of CD4 + T-cell depletion?
Esperanza Muñoz-Muela, María Trujillo-Rodríguez, Ana Serna-Gallego, et al.
The Journal of Antimicrobial Chemotherapy
|
October 17, 2019
Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
Yusnelkis Milanés-Guisado, Alicia Gutiérrez-Valencia, Juan Manuel Muñoz-Pichardo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|
December 6, 2018
Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors
Ramón Teira, Nuria Espinosa, M Mar Gutiérrez, et al.
European Journal of Internal Medicine
|
February 10, 2023
Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain
Jordi Navarro, Adrian Curran, Berta Raventós, et al.
Open Forum Infectious Diseases
|
July 31, 2023
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide-Based Regimens
Rachel L Batterham, Nuria Espinosa, Christine Katlama, et al.
Frontiers in Immunology
|
September 13, 2024
Plasma concentrations of IL-6, MIP-1β, IP-10, and PTX-3 as predictors of the immunological response to antiretroviral treatment in people with HIV
Marta Mejías-Trueba, Abraham Saborido-Alconchel, Ana Serna-Gallego, et al.
Journal of Clinical Medicine
|
September 9, 2022
Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
Javier Perez Stachowski, David Rial Crestelo, Ana Moreno Zamora, et al.
Frontiers in Immunology
|
April 3, 2023
Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered
Luis F López-Cortés, Abraham Saborido-Alconchel, María Trujillo-Rodríguez, et al.
Frontiers in Immunology
|
July 26, 2024
Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors
Abraham Saborido-Alconchel, Ana Serna-Gallego, María Trujillo-Rodriguez, et al.
Journal of the International AIDS Society
|
November 14, 2014
Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
Karin Neukam, Nuria Espinosa, Dolores Merino, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 51) with videos related to
Sort By:
Page
of 6
AIDS (London, England)
|
May 24, 2022
Anti-CD4 autoantibodies in immunological nonresponder people with HIV: cause of CD4 + T-cell depletion?
Esperanza Muñoz-Muela, María Trujillo-Rodríguez, Ana Serna-Gallego, et al.
The Journal of Antimicrobial Chemotherapy
|
October 17, 2019
Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
Yusnelkis Milanés-Guisado, Alicia Gutiérrez-Valencia, Juan Manuel Muñoz-Pichardo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|
December 6, 2018
Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors
Ramón Teira, Nuria Espinosa, M Mar Gutiérrez, et al.
European Journal of Internal Medicine
|
February 10, 2023
Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain
Jordi Navarro, Adrian Curran, Berta Raventós, et al.
Open Forum Infectious Diseases
|
July 31, 2023
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide-Based Regimens
Rachel L Batterham, Nuria Espinosa, Christine Katlama, et al.
Frontiers in Immunology
|
September 13, 2024
Plasma concentrations of IL-6, MIP-1β, IP-10, and PTX-3 as predictors of the immunological response to antiretroviral treatment in people with HIV
Marta Mejías-Trueba, Abraham Saborido-Alconchel, Ana Serna-Gallego, et al.
Journal of Clinical Medicine
|
September 9, 2022
Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
Javier Perez Stachowski, David Rial Crestelo, Ana Moreno Zamora, et al.
Frontiers in Immunology
|
April 3, 2023
Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered
Luis F López-Cortés, Abraham Saborido-Alconchel, María Trujillo-Rodríguez, et al.
Frontiers in Immunology
|
July 26, 2024
Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors
Abraham Saborido-Alconchel, Ana Serna-Gallego, María Trujillo-Rodriguez, et al.
Journal of the International AIDS Society
|
November 14, 2014
Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
Karin Neukam, Nuria Espinosa, Dolores Merino, et al.
Page
of 6